Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression
单位:[a]Division of Nephrology and Transplantation Research Center, Boston, MA, United States[b]Department of Anesthesia, Children's Hospital, Boston, MA, United States[c]Harvard Medical School, Boston, MA, United States[d]Transplant Center, Institute of Clinical and Experimental Medicine, Prague, Czech Republic[e]Department of Surgery I, Molecular Oncology and Immunology, University of Wurzburg, Wurzburg, Germany[f]Department of Cancer Biology, MD Anderson Cancer Center, TX, United States[g]Central Drug Research Institute, Lucknow, India[h]Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院器官移植研究所器官移植
We wish to thank Dr. Mohamed H. Sayegh for helpful suggestion about this work. This work was supported by National Institutes of Health Grant R01 CA131145 (to S. P.).
语种:
外文
中科院(CAS)分区:
出版当年[2011]版:
大类|2 区医学
小类|3 区肿瘤学
最新[2025]版:
大类|1 区医学
小类|2 区肿瘤学
第一作者:
第一作者单位:[a]Division of Nephrology and Transplantation Research Center, Boston, MA, United States[c]Harvard Medical School, Boston, MA, United States
通讯作者:
通讯机构:[a]Division of Nephrology and Transplantation Research Center, Boston, MA, United States[c]Harvard Medical School, Boston, MA, United States
推荐引用方式(GB/T 7714):
Basu A,Liu T,Banerjee P,et al.Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression[J].Cancer Letters.2012,321(2):doi:10.1016/j.canlet.2012.02.004.
APA:
Basu, A,Liu, T,Banerjee, P,Flynn, E,Zurakowski, D...&Pal, S.(2012).Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.Cancer Letters,321,(2)
MLA:
Basu, A,et al."Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression".Cancer Letters 321..2(2012)